The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as three phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. 

Experts in healthcare and the pharmaceutical industry have questioned Mark Cuban's ability to puncture high-priced medicines. In a 90-minute fireside chat with one of his critics, Mr. Cuban said his company has "truly changed the game."

A new phase 3 clinical trial found that Eli Lilly's weight loss drug Zepbound resulted in significantly greater weight loss than Wegovy. 

Between 2018 and 2021, more pharmacies closed in the U.S. than opened, according to research published Dec. 3 in Health Affairs.

CVS Health is preparing to raise up to $2.5 billion through a bond sale, Bloomberg reported Dec. 2. 

 Nine out of 10 drug prices negotiated by CMS remain more expensive in the U.S. compared to six other high-income countries, according to a study published Dec. 2.

Clearway Health has entered into a partnership with Sinai Chicago to expand specialty pharmacy services aimed at improving care for patients facing chronic conditions like multiple sclerosis, cancer and cystic fibrosis. 

Becker's asked pharmacy executives from hospitals and health systems across the U.S. to share their plans on improving patient care in the near future.

Amid continued demand and coverage restrictions around GLP-1s, the prices of Novo Nordisk's Ozempic and Rybelsus have dropped significantly for individuals covered by Medicare and commercial insurance, according to a new report from HHS.

Among 1,363 practicing pharmacists, 82.5% reported some familiarity with AI software, but only 38.7% said they had used it, according to survey results published Nov. 28.